ARTICLE | Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

December 6, 2017 10:07 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations.

Ayala SVP of Corporate Development Dana Gelbaum told BioCentury that the newco plans to start Phase II testing of BMS-906024 next year to treat adenoid cystic carcinoma and an undisclosed Orphan indication. Gelbaum declined to disclose next steps for BMS-986115, which has completed Phase Ib testing. BMS-906024 is administered by IV, while BMS-986115 is an oral formulation...

BCIQ Company Profiles

Bristol Myers Squibb Co.

BCIQ Target Profiles

Gamma secretase